IFI30 and breast cancer: In agreement with its known role as an important enzyme affecting immune responses to tumors [10], [12], [21], [35], the absence of GILT shows a potential pro-tumor role in breast cancer, because decreased GILT expression are observed both in primary and metastatic cancer cells compared with their adjacent normal epithelial cells.